Revenue Breakdown
Composition ()
No data
Revenue Streams
Ionis Pharmaceuticals Inc (IONS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Ionis core, accounting for 80.7% of total sales, equivalent to $234.34M. Other significant revenue streams include R&D revenue under collaborative agreements and Akcea Therapeutics. Understanding this composition is critical for investors evaluating how IONS navigates market cycles within the Biotechnology & Medical Research industry.
Profitability & Margins
Evaluating the bottom line, Ionis Pharmaceuticals Inc maintains a gross margin of 96.09%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -105.47%, while the net margin is -112.82%. These profitability ratios, combined with a Return on Equity (ROE) of -70.80%, provide a clear picture of how effectively IONS converts its operational activities into shareholder value.
Comparative Benchmarking
In the context of the broader market, IONS competes directly with industry leaders such as RGC and ASND. With a market capitalization of $13.54B, it holds a significant position in the sector. When comparing efficiency, IONS's gross margin of 96.09% stands against RGC's N/A and ASND's 90.47%. Such benchmarking helps identify whether Ionis Pharmaceuticals Inc is trading at a premium or discount relative to its financial performance.
